The cost-effectiveness of pentavalent rotavirus vaccination in England and Wales (Q38045661)

27 August 2017

The cost-effectiveness of pentavalent rotavirus vaccination in England and Wales (English)

1 reference

27 August 2017

5

Alison P Galvani

1 reference

27 August 2017

Katherine E Atkins

1

1 reference

27 August 2017

Eunha Shim

series ordinal

2

1 reference

27 August 2017

Stuart Carroll

series ordinal

3

1 reference

27 August 2017

Sibilia Quilici

series ordinal

4

1 reference

27 August 2017

language of work or name

English

0 references

publication date

21 September 2012

1 reference

27 August 2017

1 reference

27 August 2017

30

1 reference

27 August 2017

6766-6776

1 reference

27 August 2017

48

1 reference

Real-world impact of rotavirus vaccination

27 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.025

Rotavirus vaccines in Belgium: policy and impact

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.025

Impact of rotavirus vaccination on hospitalizations for rotavirus diarrhea: The IVANHOE study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.025

Summary of effectiveness and impact of rotavirus vaccination with the oral pentavalent rotavirus vaccine: a systematic review of the experience in industrialized countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.025

Herd immunity after two years of the universal mass vaccination program against rotavirus gastroenteritis in Austria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.025

Sustained decline in rotavirus detections in the United States following the introduction of rotavirus vaccine in 2006.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.025

Hospital-based surveillance of rotavirus gastroenteritis in the era of limited vaccine uptake through the private sector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.025

Rotavirus incidence and genotype distribution before and after national rotavirus vaccine introduction in Belgium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.025

The cost-effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.025

An update to “The cost-effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe”

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.025

Infant rotavirus vaccination may provide indirect protection to older children and adults in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.025

Modelling the seasonality of rotavirus disease and the impact of vaccination in England and Wales

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.025

Dynamic model of rotavirus transmission and the impact of rotavirus vaccination in Kyrgyzstan.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.025

Demographic variability, vaccination, and the spatiotemporal dynamics of rotavirus epidemics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.025

Cost-effectiveness of rotavirus vaccination in the Netherlands; the results of a consensus model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.025

Is it cost-effective to introduce rotavirus vaccination in the Dutch national immunization program?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.025

Impact of transmission dynamics on the cost-effectiveness of rotavirus vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.025

Reviewing the cost effectiveness of rotavirus vaccination: the importance of uncertainty in the choice of data sources

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.025

Impact of rotavirus vaccination on epidemiological dynamics in England and Wales.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.025

Costs of community-acquired pediatric rotavirus gastroenteritis in 7 European countries: the REVEAL Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.025

Evaluating rotavirus vaccination in England and Wales. Part II. The potential cost-effectiveness of vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.025

RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.025

Rotavirus-specific T-cell responses in young prospectively followed-up children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.025

Protective effect of naturally acquired homotypic and heterotypic rotavirus antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.025

Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.025

Efficacy of the pentavalent rotavirus vaccine, RotaTeq®, in Finnish infants up to 3 years of age: the Finnish Extension Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.025

Evaluating rotavirus vaccination in England and Wales. Part I. Estimating the burden of disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.025

Estimating the number of deaths with rotavirus as a cause in England and wales

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.025

Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.025

Safety and Efficacy of an Attenuated Vaccine against Severe Rotavirus Gastroenteritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.025

Postlicensure monitoring of intussusception after RotaTeq vaccination in the United States, February 1, 2006, to September 25, 2007

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.025

Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.025

Reduction in rotavirus-associated acute gastroenteritis following introduction of rotavirus vaccine into Australia's National Childhood vaccine schedule

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.025

Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in Ireland.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.025

Salmonella Typhimurium and Salmonella Enteritidis in England: costs to patients, their families, and primary and community health services of the NHS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.025

Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.025

Impact of program scale and indirect effects on the cost-effectiveness of vaccination programs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.025

A mathematical model of the indirect effects of rotavirus vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.025

Longitudinal study of rotavirus infections among children from Belém, Brazil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.025

Cost-effectiveness and potential impact of rotavirus vaccination in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.025

Direct and indirect effects of rotavirus vaccination: comparing predictions from transmission dynamic models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.025

10.1016/J.VACCINE.2012.09.025

7 January 2021

Identifiers

DOI

1 reference

27 August 2017

1 reference